FRMD5: A Potential Drug Target and Biomarker for Diseases (G84978)

Target Name: FRMD5

NCBI ID: G84978

FRMD5

FRMD5: A Potential Drug Target and Biomarker for Diseases

The FERM domain containing 5 (FRMD5) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The FRMD5 protein is a member of the family of transmembrane proteins, which means that it spans the cell membrane and extends into the cytoplasm. This type of protein is involved in various cellular processes, including signaling, intracellular signaling, and cell adhesion.

One of the unique features of the FRMD5 protein is its ability to interact with various signaling molecules, including TGF-β, NF-kappa-B, and SMAD. TGF-β is a cytokine that plays a role in cell growth, differentiation, and survival, while NF-kappa-B is a transcription factor that regulates inflammation and immune responses. SMAD is a protein that is involved in the regulation of gene expression, and has been implicated in various diseases, including cancer.

FRMD5 has been shown to play a role in several diseases, including cancer. For example, studies have shown that high levels of FRMD5 are associated with poor prognosis in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, FRMD5 has been shown to promote the growth and survival of cancer cells, making it a potential drug target.

In addition to its role in cancer, FRMD5 has also been implicated in neurodegenerative diseases. For example, studies have shown that FRMD5 is involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, FRMD5 has been shown to interact with dopamine, a neurotransmitter that is involved in mood, motivation, and movement. This suggests that FRMD5 may be involved in the regulation of neurotransmitter signaling in neurodegenerative diseases.

Another potential application of FRMD5 as a drug target is its role in autoimmune disorders. For example, studies have shown that FRMD5 is involved in the development and regulation of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. Additionally, FRMD5 has been shown to interact with cytokines, which are involved in the regulation of immune responses. This suggests that FRMD5 may be involved in the regulation of immune responses in autoimmune disorders.

FRMD5 has also been shown to have potential as a biomarker for various diseases. For example, studies have shown thatFRMD5 is involved in the regulation of cellular processes that are involved in disease development, including inflammation, cell death, and cell proliferation. Additionally,FRMD5 has been shown to be expressed in various tissues and fluids, including blood, urine, and synovial fluid, which suggests that it may be a useful biomarker for disease diagnosis and monitoring.

In conclusion, the FRMD5 protein is a unique and highly promising drug target and biomarker for various diseases. Its ability to interact with various signaling molecules and its involvement in several diseases make it an attractive target for drug development. Further research is needed to fully understand the role of FRMD5 in disease and its potential as a drug and biomarker.

Protein Name: FERM Domain Containing 5

Functions: May be involved in regulation of cell migration (PubMed:22846708, PubMed:25448675). May regulate cell-matrix interactions via its interaction with ITGB5 and modifying ITGB5 cytoplasmic tail interactions such as with FERMT2 and TLN1. May regulate ROCK1 kinase activity possibly involved in regulation of actin stress fiber formation (PubMed:25448675)

The "FRMD5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FRMD5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets